• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续气道正压通气作为急性高原病的辅助治疗。

Continuous positive airway pressure as adjunct treatment of acute altitude illness.

机构信息

1 Himalayan Rescue Association , Kathmandu, Nepal .

出版信息

High Alt Med Biol. 2013 Dec;14(4):405-7. doi: 10.1089/ham.2013.1059.

DOI:10.1089/ham.2013.1059
PMID:24377348
Abstract

Altitude related illness occurs in unacclimatized individuals ascending to altitudes over 2500 m. Treatment usually involves descending to lower altitudes and pharmacological therapies. There are very few cases, studies, or recommendations regarding the use of positive pressure ventilation in acute mountain sickness (AMS) or high altitude pulmonary edema (HAPE). This case describes the use of CPAP as part of the treatment of a trekker diagnosed with AMS and HAPE in a remote location at 4200 m in Nepal.

摘要

海拔相关疾病发生于未适应高海拔环境者,海拔 2500 米以上时容易发病。治疗方法通常包括下降至低海拔地区以及药物治疗。对于急性高原病(AMS)或高原肺水肿(HAPE)患者,采用正压通气治疗的案例、研究或建议非常少。本病例介绍了在尼泊尔海拔 4200 米的偏远地区,对一位徒步旅行者 AMS 和 HAPE 的诊断及治疗中,CPAP 的使用。

相似文献

1
Continuous positive airway pressure as adjunct treatment of acute altitude illness.持续气道正压通气作为急性高原病的辅助治疗。
High Alt Med Biol. 2013 Dec;14(4):405-7. doi: 10.1089/ham.2013.1059.
2
Continuous renal replacement therapy in the treatment of severe acute mountain sickness.连续性肾脏替代疗法治疗重度急性高原病
Ren Fail. 2009;31(2):175-7. doi: 10.1080/08860220802598256.
3
Altitude illness: update on prevention and treatment.高原病:预防与治疗的最新进展
Curr Sports Med Rep. 2012 May-Jun;11(3):124-30. doi: 10.1249/JSR.0b013e3182563e7a.
4
High-altitude illness.高原病
Emerg Med Clin North Am. 2004 May;22(2):329-55, viii. doi: 10.1016/j.emc.2004.02.001.
5
Treatment of high altitude diseases without drugs.不用药物治疗高原病。
Int J Sports Med. 1992 Oct;13 Suppl 1:S71-4. doi: 10.1055/s-2007-1024600.
6
High altitude, continuous positive airway pressure, and obstructive sleep apnea: subjective observations and objective data.高原、持续气道正压通气和阻塞性睡眠呼吸暂停:主观观察和客观数据。
High Alt Med Biol. 2013 Jun;14(2):186-9. doi: 10.1089/ham.2012.1085.
7
Continuous Positive Airway Pressure in the Treatment of Pediatric High Altitude Pulmonary Edema: A Case Study.持续气道正压通气治疗小儿高原性肺水肿:1 例报告。
Wilderness Environ Med. 2024 Mar;35(1):78-81. doi: 10.1177/10806032231222003. Epub 2024 Jan 10.
8
[Mountaineering and altitude sickness].[登山与高原病]
Ther Umsch. 2001 Jun;58(6):387-93. doi: 10.1024/0040-5930.58.6.387.
9
Clinical features of patients with severe altitude illness in Nepal.尼泊尔严重高原病患者的临床特征。
J Travel Med. 2008 Sep-Oct;15(5):315-22. doi: 10.1111/j.1708-8305.2008.00229.x.
10
Continuous positive airway pressure treatment for acute mountain sickness at 4240 m in the Nepal Himalaya.在尼泊尔喜马拉雅山 4240 米处用持续气道正压通气治疗急性高原病。
High Alt Med Biol. 2013 Sep;14(3):230-3. doi: 10.1089/ham.2013.1015.

引用本文的文献

1
What Is New in Altitude- and Cold-Related Illnesses of Travel: Appraisal and Summary of the Updated Guidelines from the Wilderness Medical Society.旅行中与海拔和寒冷相关疾病的新进展:荒野医学会更新指南的评估与总结
Int J Environ Res Public Health. 2025 Feb 14;22(2):284. doi: 10.3390/ijerph22020284.
2
Initial Treatment of High-Altitude Pulmonary Edema: Comparison of Oxygen and Auto-PEEP.高原性肺水肿的初始治疗:氧气与自动 PEEP 的比较。
Int J Environ Res Public Health. 2022 Dec 3;19(23):16185. doi: 10.3390/ijerph192316185.
3
High-altitude illness: Management approach.
高原病:管理方法。
Turk J Emerg Med. 2019 Sep 19;19(4):121-126. doi: 10.1016/j.tjem.2019.09.002. eCollection 2019 Oct.
4
An Approach to Children with Pulmonary Edema at High Altitude.一种针对高海拔地区肺水肿患儿的治疗方法。
High Alt Med Biol. 2018 Mar;19(1):91-98. doi: 10.1089/ham.2017.0096. Epub 2018 Feb 22.
5
Acute high-altitude sickness.急性高原病
Eur Respir Rev. 2017 Jan 31;26(143). doi: 10.1183/16000617.0096-2016. Print 2017 Jan.